AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

COCHLEAR LTD

99.890

+1.6701.70%

Volume:609.26K

Turnover:60.59M

Market Cap:6.53B

PE:18.96

High:100.490

Open:96.900

Low:96.500

Close:98.220

52wk High:313.284

52wk Low:88.740

Shares:65.40M

Float Shares:65.14M

Volume Ratio:0.86

T/O Rate:0.94%

Dividend:4.30

Dividend Rate:4.31%

EPS(TTM):5.268

EPS(LYR):5.943

ROE:18.15%

ROA:11.28%

PB:3.37

PE(LYR):16.81

Loading ...

Overview Company News Filings

Australian Dollar Reaches Four-Year Peak: Which ASX Stocks Stand to Gain?

Assessing Cochlear’s Valuation After Its FY26 Earnings Guidance Downgrade

Simply Wall St.

Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX

MT Newswires Live

How Cochlear’s FY26 Profit Downgrade At Cochlear (ASX:COH) Has Changed Its Investment Story

Simply Wall St.

Cochlear Needs to Keep Promoting Implants as Volume Delays Not Structural, Says Jefferies, Shares Up 4%

MT Newswires Live

Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk

ASX Biggest Losers

MT Newswires Live

Cochlear (ASX:COH) Valuation Check After Guidance Cut And Global Demand Challenges

Simply Wall St.

Cochlear (ASX:COH) Is Down 44.0% After Cutting Profit Outlook Amid Softer Demand And Cost Reset

Simply Wall St.

BUZZ-Australia's Cochlear set for worst week ever on earnings forecast cut

Jarden Adjusts Cochlear's Price Target to AU$169 from AU$224, Keeps at Neutral

MT Newswires Live

Stock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut

Jarden Analysts See Some Hope for Cochlear -- Market Talk

Cochlear Has Limited Scope for Sales Recovery -- Market Talk

Cochlear's Outlook Is Unclear Despite Margin Support -- Market Talk

BUZZ-Citi reduces PT for Australia's Cochlear post weak trading update

3 ASX Stocks Estimated To Be Undervalued By Up To 48.5%

Simply Wall St.

Asia Morning Call-Global Markets

BUZZ-Sonova leads European hearing-care stocks lower after Cochlear warning

Cochlear Bull Thinks Volumes Can Recover With Time -- Market Talk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/COH.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"COH.AU\",,,,,undefined,":{"symbol":"COH.AU","market":"AU","secType":"STK","nameCN":"COCHLEAR LTD","latestPrice":99.89,"timestamp":1778220720000,"preClose":98.22,"halted":0,"volume":609259,"delay":0,"changeRate":0.01700264711871311,"nameEN":"COCHLEAR LTD","floatShares":65138365,"shares":65398462,"eps":5.268067,"marketStatus":"Market Closed","change":1.67,"latestTime":"05-08 16:12:00 AEST","open":96.9,"high":100.49,"low":96.5,"amount":60593193,"amplitude":0.040623,"askPrice":100.13,"askSize":283,"bidPrice":99.5,"bidSize":100,"shortable":3,"etf":0,"ttmEps":5.268067,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1778457600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":98.22,"dividendRate":0.043067,"openAndCloseTimeList":[[1778198400000,1778220000000]],"volumeRatio":0.8593414572151264,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"COH.AU","preClose":98.22,"auctionPrice":99.85,"auctionVolume":177758,"auction":3,"marketStatus":"盘后竞价","timestamp":1778220599558}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"COH.AU\",,,,,undefined,":{"symbol":"COH.AU","floatShares":65138365,"roa":"11.28%","roe":"18.15%","lyrEps":5.943021,"volumeRatio":0.8593414572151264,"shares":65398462,"dividePrice":4.302,"high":100.49,"amplitude":0.040623,"preClose":98.22,"low":96.5,"week52Low":88.74,"pbRate":"3.37","psRate":"2.79","week52High":313.284,"institutionHeld":0,"latestPrice":99.89,"committee":-0.477807,"eps":5.268067,"divideRate":0.043067,"volume":609259,"delay":0,"ttmEps":5.268067,"open":96.9,"prevYearClose":257.41,"prevWeekClose":98.77,"prevMonthClose":94,"prevQuarterClose":169.1,"fiveDayClose":98.77,"twentyDayClose":172.1,"sixtyDayClose":251.613,"dividendPayoutRate":0.7151245132736365,"dividendGrowthYears":4,"dividendGrowthRate":0.13333333333333333,"fiveYearAvgDividendRate":0.011947843137511144},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COH.AU\",params:#limit:5,,,undefined,":[{"date":"2026-03-19","symbol":"COH.AU","amount":2.15,"announcedDate":"2026-02-12","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-20","name":"COCHLEAR LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-13","payableDate":"2026-03-20","currency":"AUD","dateTimestamp":1773838800000,"payDate":"2026-04-13"},{"date":"2026-02-13","symbol":"COH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770937200000,"name":null,"time":"","dateTimestamp":1770901200000,"actualEps":null},{"date":"2025-09-18","symbol":"COH.AU","amount":2.15,"announcedDate":"2025-08-15","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-19","defaultRemindTime":1758153600000,"name":"COCHLEAR LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-13","payableDate":"2025-09-19","currency":"AUD","dateTimestamp":1758117600000,"payDate":"2025-10-13"},{"date":"2025-08-15","symbol":"COH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755216000000,"name":null,"time":"","dateTimestamp":1755180000000,"actualEps":null},{"date":"2025-03-20","symbol":"COH.AU","amount":2.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-03-21","name":"COCHLEAR LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-14","payableDate":"2025-03-21","currency":"AUD","dateTimestamp":1742389200000,"payDate":"2025-04-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COH.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2021-03-25","recordDate":"2021-03-26","paymentDate":"2021-04-20","value":1.15,"currency":"AUD"},{"executeDate":"2021-09-23","recordDate":"2021-09-24","paymentDate":"2021-10-18","value":1.4,"currency":"AUD"},{"executeDate":"2022-03-28","recordDate":"2022-03-29","paymentDate":"2022-04-21","value":1.55,"currency":"AUD"},{"executeDate":"2022-09-21","recordDate":"2022-09-23","paymentDate":"2022-10-17","value":0.87,"currency":"AUD"},{"executeDate":"2023-03-21","recordDate":"2023-03-22","paymentDate":"2023-04-14","value":1.0075,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COH.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131057162","title":"Australian Dollar Reaches Four-Year Peak: Which ASX Stocks Stand to Gain?","url":"https://stock-news.laohu8.com/highlight/detail?id=1131057162","media":"Trading Random","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131057162?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:51","pubTimestamp":1778118672,"startTime":"0","endTime":"0","summary":"Amidst the constant stream of significant global developments, it can be challenging to monitor shifts within the Australian financial sector. Observant investors, however, will have noticed a major...","market":null,"thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800965.SGD","BK4155","LU0823411888.USD","BK4533","LU0211327993.USD","LU1267930490.SGD","BK4588","LU0052756011.USD","BK4504","BK4156","LU2237443622.USD","BK4585","CSL.AU","BK4220","LU1267930227.SGD","BK4596","BK4076","WES.AU","BK4017","LU0211328371.USD","LU2237443549.SGD","BK4213","WHC.AU","LU1244550494.USD","WDS.AU","BK4114","LU0128525689.USD","BK7142","COH.AU","BK4597","LU2237443978.SGD","BK4532","BHP.AU","LU1244550577.SGD","LU0310799852.SGD","JBH.AU","LU2237443382.USD","BK4138","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632279932","title":"Assessing Cochlear’s Valuation After Its FY26 Earnings Guidance Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2632279932","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632279932?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:16","pubTimestamp":1777889791,"startTime":"0","endTime":"0","summary":"Cochlear (ASX:COH) has been in focus after a significant downgrade to its FY26 earnings guidance, with management pointing to softer demand, delayed surgeries, and Middle East disruptions as key pressures on near term performance.\nSee our latest analysis for Cochlear.\nThe share price shock from the April guidance downgrade still dominates the picture, with a 30 day share price return of 41.83% and a year to date share price return of 61.59%. The 1 year total shareholder return of 62.03% and 5...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlears-valuation-after-its-fy26-earnings-guidan","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlears-valuation-after-its-fy26-earnings-guidan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632987285","title":"Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2632987285","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632987285?lang=en_us&edition=fundamental","pubTime":"2026-05-04 11:54","pubTimestamp":1777866873,"startTime":"0","endTime":"0","summary":"CSL  led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed  and Cochlear  followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COH.AU","DBB","BK7067","LU0728928796.USD","SG9999004303.SGD","BK7508","XJO.AU","BK4086","CSL.AU","RMD.AU","BK7511","CSL","LU1169590202.USD","BK7501","BK7007","LU1169589451.USD","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623295","title":"How Cochlear’s FY26 Profit Downgrade At Cochlear (ASX:COH) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623295","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623295?lang=en_us&edition=fundamental","pubTime":"2026-05-02 03:48","pubTimestamp":1777664927,"startTime":"0","endTime":"0","summary":"Cochlear Limited recently downgraded its FY26 net profit guidance from A$435–A$460 million to A$290–A$330 million, citing softer demand, delayed surgeries, and geopolitical disruptions in key markets.\nThis setback has drawn attention to how dependent Cochlear’s earnings are on procedure volumes and hospital capacity, despite its strong competitive position in implantable hearing solutions.\nWe’ll now examine how this earnings guidance cut, driven by weaker demand and delayed surgeries, may...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-cochlears-fy26-profit-downgrade-at-cochlear-asxcoh-has-c","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/how-cochlears-fy26-profit-downgrade-at-cochlear-asxcoh-has-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631714502","title":"Cochlear Needs to Keep Promoting Implants as Volume Delays Not Structural, Says Jefferies, Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631714502","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631714502?lang=en_us&edition=fundamental","pubTime":"2026-04-30 14:42","pubTimestamp":1777531352,"startTime":"0","endTime":"0","summary":"Cochlear's  current volume delays are not structural as its volume opportunity for implants remains strong, Jefferies said in a Wednesday note.Jefferies said that US Medicare Advantage and commercial insurance providers require prior authorization for cochlear implantation procedures, which is causing delays in cochlear implant procedure volumes.Cochlear needs to continue promoting the benefits of cochlear implants while also expanding its advocacy programs to support patient access and awareness, the investment firm added.Jefferies kept a buy rating on Cochlear with a price target of AU$137.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631569798","title":"Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2631569798","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631569798?lang=en_us&edition=fundamental","pubTime":"2026-04-29 14:59","pubTimestamp":1777445940,"startTime":"0","endTime":"0","summary":"0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630652359","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2630652359","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630652359?lang=en_us&edition=fundamental","pubTime":"2026-04-27 11:59","pubTimestamp":1777262349,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech : -3%, AU$42.79NexGen Energy : -3%, AU$17.26Telix Pharmaceuticals : -2%, AU$14.47Cochlear : -2%, AU$94.76Paladin Energy : -2%, AU$12.28Origin Energy : -2%, AU$12.44EVT : -2%, AU$12.44Tuas : -2%, AU$5.97Ramsay Health Care : -2%, AU$39.15Southern Cross Gold : -2%, AU$11.07","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7130","BK7507","COH.AU","PDN.AU","ORG.AU","BK7113","TUA.AU","BK7042","BK7104","BK7007","BK7509","BK7067","NXG.AU","SX2.AU","BK7503","RHC.AU","BK7035","BK7016","EVT.AU","BK7006","WTC.AU","BK7083","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630740978","title":"Cochlear (ASX:COH) Valuation Check After Guidance Cut And Global Demand Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2630740978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630740978?lang=en_us&edition=fundamental","pubTime":"2026-04-25 10:12","pubTimestamp":1777083176,"startTime":"0","endTime":"0","summary":"Cochlear (ASX:COH) is back in focus after the company cut its fiscal year profit guidance, citing softer demand in the US, surgical capacity constraints in Western Europe, and external risks in China and the Middle East.\nSee our latest analysis for Cochlear.\nThe steep guidance cut has been met with a sharp reset in sentiment, with a 7 day share price return of 42.21% decline and a 1 year total shareholder return of 62.47% decline pointing to fading momentum, even as management reiterates its...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-check-after-guidance-cut-and-globa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-valuation-check-after-guidance-cut-and-globa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629489319","title":"Cochlear (ASX:COH) Is Down 44.0% After Cutting Profit Outlook Amid Softer Demand And Cost Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2629489319","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629489319?lang=en_us&edition=fundamental","pubTime":"2026-04-24 09:08","pubTimestamp":1776992934,"startTime":"0","endTime":"0","summary":"Cochlear Limited recently cut its fiscal-year profit outlook after softer-than-expected demand, citing weaker US consumer sentiment, surgical capacity constraints in Western Europe, and external headwinds including geopolitical tensions and reduced reimbursement in China.\nWhile management reiterated confidence in its long-term growth strategy, it also flagged the need to reshape its cost base to better align with current demand conditions and external risks.\nWe’ll now examine how the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-is-down-440-after-cutting-profit-outlook-ami","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-asxcoh-is-down-440-after-cutting-profit-outlook-ami","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIX","BK4551","BK4588","BK4023","BK4528","AI","CHAT","COH.AU","BK7007","AIPO","ARTY","AIYY","BK4585","BK4587","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629886708","title":"BUZZ-Australia's Cochlear set for worst week ever on earnings forecast cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2629886708","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629886708?lang=en_us&edition=fundamental","pubTime":"2026-04-24 08:51","pubTimestamp":1776991888,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cochlear set for worst week ever on earnings forecast cut** Shares of Cochlear COH.AX on track for worst week ever, down 42.7%** Stock's relative strength index remains below 30, a level widely seen as signalling oversold conditions** COH stock crashed over 40% on Wednesday after co slashed its forecast for annual earnings** Citi downgraded rating to \"sell\", reduced price target to A$95/shr on Thursday** \"This guidance downgrade is far worse than anticipated\" - Jarden on Wednesday** Stock down 62.8% YTD, including the day's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL4N41703K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","COH.AU","CNS","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629841608","title":"Jarden Adjusts Cochlear's Price Target to AU$169 from AU$224, Keeps at Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2629841608","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629841608?lang=en_us&edition=fundamental","pubTime":"2026-04-23 17:41","pubTimestamp":1776937271,"startTime":"0","endTime":"0","summary":"Cochlear (ASX:COH) has an average rating of overweight and mean price target of AU$166.45, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169620205","title":"Stock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=1169620205","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169620205?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:22","pubTimestamp":1776914566,"startTime":"0","endTime":"0","summary":"Cochlear Ltd's stock fell 5.02% during intraday trading on Thursday, extending recent heavy losses for the hearing implant maker.The decline follows a series of analyst rating downgrades and a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629355070","title":"Jarden Analysts See Some Hope for Cochlear -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2629355070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629355070?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:34","pubTimestamp":1776908040,"startTime":"0","endTime":"0","summary":"0134 GMT - Cochlear won't get a good start to its next fiscal year but there is still some cause for optimism, Jarden analysts say. While the hearing implant maker has slashed its FY 2026 profit guidance on weak unit sales, the Jarden analysts tell clients in a note that the Australian company's services segment appears to be rebounding into fiscal 2027. Elsewhere, they acknowledge that competition is making acoustics revenue growth unpredictable, but still cite 11% March-quarter growth as a positive. Jarden cuts its target price on the stock 25% to A$169.00 and maintains a neutral rating. Shares are down 1.4% at A$98.19. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","HOPE","BK4211","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629778620","title":"Cochlear Has Limited Scope for Sales Recovery -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2629778620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629778620?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:04","pubTimestamp":1776906240,"startTime":"0","endTime":"0","summary":"0104 GMT - Cochlear loses its buy rating at UBS, where analysts see limited scope for the hearing-implant maker to lift annual sales growth back to 10% any time soon. Cutting their recommendation to neutral, the investment bank's analysts tell clients that a drop in U.S. unit sales at a time when Cochlear is releasing a new implant into a vast underpenetrated adult market is a clear negative. They say that overburdened European health systems and reimbursement cuts in China add to the pressure on sales. The analysts warn that the challenges facing the Australian company are entrenched, with earnings visibility at a post-Covid low. UBS slashes its target price 64% to A$109.00. Shares are down 2.2% at A$97.40. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629307269","title":"Cochlear's Outlook Is Unclear Despite Margin Support -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2629307269","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629307269?lang=en_us&edition=fundamental","pubTime":"2026-04-23 08:39","pubTimestamp":1776904740,"startTime":"0","endTime":"0","summary":"0039 GMT - Cochlear's decision to cut manufacturing and accelerate restructuring should help support margins, but the outlook remains unclear, according to Macquarie analysts. They are positive on the hearing-implant maker's decision to shrink manufacturing output by more than the fall in sales, telling clients in a note that this will reduce inventory. However, they warn that hearing care has been deprioritized by U.S. consumers and European healthcare systems, and see the risk that weak consumer sentiment could also weigh on processor upgrade volumes. Macquarie cuts its target price 52% to A$115.00 and stays neutral on the stock, which is down 1.1% at A$98.51. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629807332","title":"BUZZ-Citi reduces PT for Australia's Cochlear post weak trading update","url":"https://stock-news.laohu8.com/highlight/detail?id=2629807332","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629807332?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:48","pubTimestamp":1776890890,"startTime":"0","endTime":"0","summary":"BUZZ-Citi reduces PT for Australia's Cochlear post weak trading update** Analysts at Citi said Cochlear's COH.AX trading update on Wednesday highlighted a \"laundry list of headwinds far beyond what we think most anticipated\"** Shares of the hearing implants maker crashed over 40% on Wednesday after a weak trading update** Brokerage reduces price target for stock to A$95/shr; downgrades rating to \"sell\"** Citi sees lower-than-expected demand for implants from co in developed markets amid persistent reductions in discretionary spending; brokerage cut its forecast for implant growth rate from high to mid-single digits** Brokerage lowers FY26 NPAT estimates for firm by 22%** COH down 61.8% YTD, as of last close","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4N4152GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629075751","title":"3 ASX Stocks Estimated To Be Undervalued By Up To 48.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629075751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629075751?lang=en_us&edition=fundamental","pubTime":"2026-04-23 03:04","pubTimestamp":1776884683,"startTime":"0","endTime":"0","summary":"In the last week, the Australian market has stayed flat, yet it is up 14% over the past year with earnings forecasted to grow by 12% annually. In this context of steady growth and positive earnings outlook, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on market inefficiencies.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/3-asx-stocks-estimated-to-be-undervalued-by-up-to-485","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/3-asx-stocks-estimated-to-be-undervalued-by-up-to-485","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RDY.AU","BK7094","BK7043","NXL.AU","CGS.AU","SDR.AU","TPW.AU","COH.AU","WRK.AU","BK7049","GMD.AU","JDO.AU","BK7135","BK7016","BK7007","BK7062","LGI.AU","ELS.AU","BK7084","BK7104","BK7107","MFG.AU","BK7060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629024367","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2629024367","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629024367?lang=en_us&edition=fundamental","pubTime":"2026-04-23 02:30","pubTimestamp":1776882635,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsApril 23 (Reuters) -  Stock Markets  closing level)Net ChngStock MarketsNet ChngS&P/ASX 200**8843.6-105.8NZX 50**12945.613.27DJIA49360.05210.67NIKKEI**59585.86236.69Nas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4N41524Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BHP.AU","BK7507","BK7007","COH.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629133380","title":"BUZZ-Sonova leads European hearing-care stocks lower after Cochlear warning","url":"https://stock-news.laohu8.com/highlight/detail?id=2629133380","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629133380?lang=en_us&edition=fundamental","pubTime":"2026-04-22 16:02","pubTimestamp":1776844978,"startTime":"0","endTime":"0","summary":"BUZZ-Sonova leads European hearing-care stocks lower after Cochlear warning** Shares in Sonova SOON.S fall over 4%, leading a drop in sector peers after Australian hearing-implant maker Cochlear COH.AX cut its FY forecast, citing uncertainty and weaker demand tied to the Middle East war** \"While the generally more challenging market environment may also affect Sonova, the impact should be limited given the relatively small contribution of cochlear implants to Sonova's overall business,\" says Vontobel analyst Sibylle Bischofberger** Cochlear implants account for around 8% of the Swiss hearing aid maker's group sales, the analyst says** Elsewhere in the hearing-care sector, Amplifon AMPF.MI and Demant DEMANT.CO down over 2%, GN Store Nord GN.CO down 1.6%, following a 41% slide in Cochlear shares** Softening cochlear demand in developed markets, reimbursement pressure in China, and Middle East-led disruption point to a weaker, more prolonged downcycle, Jefferies says** Including Wednesday","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL8N4150HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629092926","title":"Cochlear Bull Thinks Volumes Can Recover With Time -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2629092926","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629092926?lang=en_us&edition=fundamental","pubTime":"2026-04-22 14:33","pubTimestamp":1776839580,"startTime":"0","endTime":"0","summary":"0633 GMT - Cochlear's bull at Jefferies slashes their target price on the hearing-implant maker's guidance downgrade while thinking market volumes can recover over the longer term. Analyst David Stanton tells clients in a note that the investment bank's channel checks suggest that health insurers in developed and developing markets are under pressure, which leads to delays in demand for implants. Stanton points out that insurers in developed markets are increasing deductibles, while many patients see implantation as a semi-elective procedure that can be delayed. Jefferies cuts its target price 52% to A$137.00 and keeps a buy rating on the stock, which closed 41% lower at A$99.58. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","COH.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":97,"code":"91000000","status":"200"}]}}